Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Alimera Sciences, Inc. is a biopharmaceutical company focused on the commercialization and development of prescription ophthalmic pharmaceuticals, particularly for retinal diseases. Its flagship product, ILUVIEN, is used for the treatment of diabetic macular edema, primarily in the U.S. and European markets, which provides a unique competitive advantage due to its patented delivery system that allows for sustained release of medication over an extended period.
Alimera generates revenue primarily through the sale of ILUVIEN, which is priced at approximately $28,000 per treatment. The company benefits from a high gross margin of 75.7%, which is indicative of strong pricing power in the specialty pharmaceutical market. Its competitive advantage lies in the unique formulation and delivery mechanism of ILUVIEN, which differentiates it from traditional therapies.
Regulatory approvals for new indications of ILUVIEN
Sales growth in the U.S. and European markets
Partnership developments or licensing agreements
Changes in reimbursement policies affecting ILUVIEN
Regulatory changes that could impact drug approval processes
Technological advancements in alternative therapies for retinal diseases
Emergence of new competitors with innovative treatments for diabetic macular edema
Potential for generic competition as patents expire
High debt-to-equity ratio (1.46) indicating potential liquidity risks
Negative operating cash flow impacting financial stability
moderate - The demand for specialty pharmaceuticals can be somewhat insulated from economic cycles, but overall healthcare spending is influenced by GDP growth.
Alimera's operations are less sensitive to interest rates, but rising rates could increase the cost of capital for future financing needs, potentially impacting growth initiatives.
minimal - Alimera's current debt levels are manageable, and it does not heavily rely on credit for operations.
growth - Investors looking for high growth potential in the specialty pharmaceutical sector.
high - The stock has shown significant price volatility, with a 1-year return of 110.6%.
